S

SAB

Develops fully human polyclonal antibodies

Director Analytical Development

Full-Time
$190k - $235k/yr
Expert
Bachelor's, PhD
Remote in USA
RemoteRegular travel to Sioux Falls, South Dakota, and occasional vendor-partner visits required (about 25–30%).
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • An advanced degree in Biochemistry, Biophysics, or a related discipline; a PhD is preferred.
  • At least 8 years of biopharma industry experience, including at least 4 years in a management role in analytical development for biologics.
  • Hands-on expertise in A280, high-performance liquid chromatography, capillary electrophoresis, liquid chromatography-mass spectrometry, enzyme-linked immunosorbent assay, and cell-based potency methods for biologics.
  • Proficiency in trend analysis and simple statistical analysis.
  • Strong understanding of phase-appropriate analytical control strategies, method validation and transfer, applicable guidelines including ICH Q2(R2), ICH Q14, FDA guidance documents and USP chapters, and current Good Manufacturing Practice requirements.
  • Experience with reference standard programs, critical reagent programs, and forced degradation studies.
  • Demonstrated success supporting regulatory submissions, including IND/IMPD and BLA/MAA.
  • Experience managing external partners and driving outsourced analytical activities.
  • Strong written and verbal communication and technical writing skills, and ability to present information in one-on-one, departmental, and cross-functional meetings.
  • Proficiency in Microsoft Word, Excel, PowerPoint, and Outlook.
  • Ability to travel regularly to company locations in Sioux Falls, South Dakota, and occasionally to vendor partner locations; travel is approximately 25–30%.
  • Ability to regularly move up to 10 pounds; close and peripheral vision and ability to adjust focus are required.
Responsibilities
  • Provide strategic and technical leadership for biologics analytical development activities, including phase-appropriate analytical control strategies, late-stage and commercial assay reduction strategy, method development, validation, transfer to internal and external quality control laboratories, and lifecycle management.
  • Ensure analytical readiness for late-stage development, process performance qualification, and commercial launch of the SAB-142 polyclonal antibody program.
  • Oversee and perform hands-on analytical work at the company's development and Good Manufacturing Practice laboratories.
  • Provide hands-on and supervisory support for method troubleshooting, optimization and bridging; method performance monitoring; investigations of deviations, system suitability failures, out-of-trend results, and out-of-specification results; corrective and preventive action; change control; and continuous method improvement.
  • Lead and manage the reference standard and critical reagent programs, extended characterization strategies and testing, forced degradation and stress-sample studies, comparability, and specification setting.
  • Ensure internal and external partner analytical activities are scientifically rigorous, compliant with current Good Manufacturing Practice, ICH, USP and global regulations, and aligned with Quality by Design principles, industry best practices, and company quality standards.
  • Author and own regulatory CMC analytical sections and provide technical input across CMC-related sections.
  • Scale analytical capabilities; oversee equipment qualification and maintenance; implement workflows and laboratory information management systems; and design and establish a non-GMP development laboratory area.
  • Provide signature authorization for analytical documents and data.
  • Partner with Quality Control and Quality Assurance to establish, maintain, and oversee analytical quality, Good Manufacturing Practice compliance infrastructure, and inspection readiness for internal and external analytical documents and data.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • Experience in flow cytometry.
  • Experience in late-phase pre-commercial biotech or pharmaceutical environments.

About the company

SAB Biotherapeutics uses the DiversitAb platform to produce fully human polyclonal antibodies in genetically engineered transchromosomic cattle, removing the need for human donors. These antibodies are designed to treat immunology disorders and infectious diseases and include programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. difficile infection. The platform can shorten development timelines, aiming to move candidates from concept to clinic in under five months, and it focuses on polyclonal antibodies rather than monoclonal ones. The company pursues regulatory approval and commercialization through collaborations with government agencies, academia, and pharmaceutical partners to address high-need diseases and biodefense applications.

Company Size

51-200

Company Stage

IPO

Headquarters

Miami Beach, Florida

Founded

2014

Get referred to SAB

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Over 60 SAFEGUARD sites were active by August 2026, accelerating enrollment.
  • Part A completed in Q1 2026, and Part B targets 159 patients.
  • SAB still expects runway through 2028, reducing near-term financing risk.

What critics are saying

  • SAB burned through another $85 million in March 2026, signaling relentless dilution pressure.
  • SAFEGUARD data arrive in 2H 2027; any efficacy miss destroys the T1D story.
  • One-program dependence makes SAB existentially fragile if SAB-142 fails or FDA demands a new trial.

What makes SAB unique

  • SAB BIO's Tc cattle platform generates fully human polyclonal antibodies without human donors.
  • SAB-142 entered registrational Phase 2b SAFEGUARD in March 2026, de-risking the lead program.
  • Sanofi joined SAB's July 2025 $175 million financing, validating the platform commercially.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

3%

2 year growth

0%
Investing.com
Mar 18th, 2026
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com

SAB Biotherapeutics prices $85M stock offering at $3.85/share

Seeking Alpha
Mar 17th, 2026
SAB Biotherapeutics launches stock offering to fund SAB-142 diabetes treatment; shares fall 6.9%

SAB Biotherapeutics has launched an underwritten public offering of common stock and pre-funded warrants. The company is offering securities directly, with underwriters having the option to purchase up to 15% additional securities within 30 days. Proceeds will primarily fund development of SAB-142, the company's lead candidate for Type 1 Diabetes. The funds will also support clinical trials, manufacturing, regulatory activities and general corporate expenses. Shares fell 6.9% in post-market trading following the announcement.

Associated Press
Mar 9th, 2026
SAB BIO raises $175M, advances T1D therapy SAB-142 into registrational Phase 2b trial

SAB Biotherapeutics has reported full year 2025 financial results whilst advancing its lead candidate SAB-142 for type 1 diabetes. The company raised $175 million in an oversubscribed private placement including strategic investor Sanofi, providing operational runway through 2028. SAB has dosed multiple patients in its registrational Phase 2b SAFEGUARD study, with enrollment on track to complete by end of 2026 and topline data expected in second half of 2027. Phase 1 data released in December 2025 confirmed SAB-142's favourable safety profile, showing no serum sickness and low immunogenicity across all cohorts. The company ended 2025 with cash and securities of $143.5 million. Research and development expenses were $34.4 million, up from $30.3 million in 2024.

Money Controller
Jul 21st, 2025
SAB Biotherapeutics: $175M Private Placement Announced

SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from Sanofi and other investors. The funds will support the Phase 2b SAFEGUARD study of SAB-142 for autoimmune T1D and extend the cash runway to mid-2028. The deal includes issuing Series B nonvoting convertible preferred stock and warrants for potential additional proceeds of $284 million. The private placement is expected to close on July 22, 2025, subject to conditions.

GlobeNewswire
Jul 21st, 2025
SAB BIO Announces Oversubscribed $175 Million Private Placement

SAB BIO Announces Oversubscribed $175 Million Private Placement...